Equities
  • Price (EUR)104.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change34.52%
  • Beta--
Data delayed at least 15 minutes, as of Feb 21 2020.
More ▼

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

  • Revenue in USD (TTM)7.73bn
  • Net income in USD835.00m
  • Incorporated1996
  • Employees46.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Memorial Hermann Healthcare System-Laboratories and Service CentersAnnounced27 Jan 202027 Jan 2020Announced4.55%--
Blueprint Genetics OyDeal completed22 Jan 202022 Jan 2020Deal completed4.98%--
Data delayed at least 15 minutes, as of Feb 24 2020 15:22 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.